Harold J. Burstein, MD, PhD, on Results of the CREATE-X Clinical Trial on Higher-Risk Disease
2015 San Antonio Breast Cancer SymposiumHarold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, discusses the CREATE-X adjuvant study of capecitabine in high-risk patients with residual disease (Abstract S6-01).
Related Videos
Lisa Carey, MD, and Kathy Albain, MD, on Results of the SWOG-8814 Trial
Lisa A. Carey, MD, of the University of North Carolina, and Kathy S. Albain, MD, of Loyola University Medical Center, discuss molecular predictors of outcome on ad...
Jame Abraham, MD, on HER2-Positive Breast Cancer: Results of the BCIRG-006 Study
Jame Abraham, MD, of the Cleveland Clinic, discusses the 10-year follow-up of this trial, and the long-term benefit and safety of adding trastuzumab to the adjuvant treatment of HE...
Sherene Loi, MD, on Triple-Negative Breast Cancer: A Pooled Data Analysis
Sherene Loi, MD, of Peter MacCallum Cancer Centre, discusses a pooled individual patient data analysis of stromal tumor-infiltrating lymphocytes in primary triple-negative breast c...
Clifford Hudis, MD, and Carlos Arteaga, MD, on Metabolic Syndrome and Obesity in Breast Cancer
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Carlos L. Arteaga, MD, of Vanderbilt University, discuss the roles of IGF/insulin signaling, ...
Clifford Hudis, MD, and Julia White, MD, on Early-Stage Breast Cancer: Hypofractionated Radiotherapy
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and Julia R. White, MD, of Ohio State University Comprehensive Cancer Center, discuss a meta-anal...
